Jun 21 |
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
|
Jun 11 |
Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock
|
May 14 |
Aprea Therapeutics GAAP EPS of -$0.67
|
May 14 |
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
|
May 13 |
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
|
May 2 |
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Apr 10 |
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
|
Apr 3 |
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
|
Mar 11 |
Aprea Therapeutics announces private placement financing of up to $34M
|
Mar 11 |
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
|